Kiora Pharmaceuticals Inc...

3.20
0.08 (2.56%)
At close: Apr 24, 2025, 3:59 PM
3.30
3.12%
After-hours: Apr 24, 2025, 07:32 PM EDT
2.56%
Bid 2.8
Market Cap 9.6M
Revenue (ttm) 16.02M
Net Income (ttm) 3.59M
EPS (ttm) 0.87
PE Ratio (ttm) 3.68
Forward PE -1.22
Analyst Buy
Ask 3.34
Volume 5,373
Avg. Volume (20D) 22,977
Open 3.18
Previous Close 3.12
Day's Range 3.06 - 3.29
52-Week Range 2.51 - 5.55
Beta -0.53

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, a...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 13, 2015
Employees 12
Stock Exchange NASDAQ
Ticker Symbol KPRX
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for KPRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 212.50% from the latest price.

Stock Forecasts

Next Earnings Release

Kiora Pharmaceuticals Inc. is scheduled to release its earnings on May 9, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription